A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab in First-line HER2-positive Breast Cancer (DESTINY-Breast09).

Condition: First-line HER2-positive Breast Cancer (DESTINY-Breast09).

Sponsor: AstraZeneca

A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab in First-line HER2-positive Breast Cancer (DESTINY-Breast09). The study is a randomized, multi-center, phase III study to evaluate the efficacy and safety of T-DXd with or without pertuzumab compared to SOC in HER2-positive breast cancer patients with no prior HER2-targeted therapy or chemotherapy in the unresectable or metastatic setting.


Go To Trial Homepage